Pituitary ACTH Hypersecretion: all 64 studies

Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)RecruitingNCT07920198
• PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary TumoursNot yet recruitingNCT07813351Phase 3
• Combination Osilodrostat and Cabergoline in Cushing's DiseaseEnrolling by invitationNCT07603466Phase 4
• Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.RecruitingNCT07463625
• FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing DiseaseRecruitingNCT07460232Early Phase 1
• Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary TumorsRecruitingNCT07335315
• Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's DiseaseEnrolling by invitationNCT07108244Not applicable
• Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CTRecruitingNCT06962202
• Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma DetectionNot yet recruitingNCT06701838
• Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseRecruitingNCT05971758Phase 2
• DDAVP for Pituitary AdenomaRecruitingNCT04569591Not applicable
• Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)RecruitingNCT04543253
• Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid DisordersRecruitingNCT04374721Not applicable
• Long-Term Follow-Up of Survivors of Pediatric Cushing DiseaseRecruitingNCT03831958
• Collecting Information About Treatment Results for Patients With Cushing's SyndromeRecruitingNCT03364803
• An Investigation of Pituitary Tumors and Related Hypothalmic DisordersRecruitingNCT00001595
• A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCompletedNCT03697109Phase 3Results posted
• Open-label Treatment in Cushing's SyndromeCompletedNCT03621280Phase 3Results posted
• Study to Evaluate CORT125134 in Participants With Cushing's SyndromeCompletedNCT02804750Phase 2Results posted
• Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseCompletedNCT02697734Phase 3Results posted
• Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseCompletedNCT02310269Results posted
• Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyCompletedNCT02060383Phase 4Results posted
• Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseTerminatedNCT01915303Phase 2Results posted
• Treatment for Endogenous Cushing's SyndromeCompletedNCT01838551Phase 3Results posted
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 4Results posted
• An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.CompletedNCT01582061Phase 3Results posted
• Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's DiseaseCompletedNCT01374906Phase 3Results posted
• Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCompletedNCT01371565Phase 3Results posted
• Safety and Efficacy of LCI699 in Cushing's Disease PatientsCompletedNCT01331239Phase 2Results posted
• Prevention of Metabolic Complications of Glucocorticoid ExcessCompletedNCT01319994Phase 2/3Results posted
• An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00936741Phase 3Results posted
• Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)TerminatedNCT00612066Phase 2Results posted
• A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00569582Phase 3Results posted
• Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's DiseaseCompletedNCT00434148Phase 3Results posted
• Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's DiseaseCompletedNCT00171951Phase 2Results posted
• A Trial of Lu AG13909 in Adult Participants With Cushing's DiseaseActive, not recruitingNCT06471829Phase 2
• A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeCompletedNCT05804669Phase 1/2
• SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's SyndromeCompletedNCT05307328Phase 2
• Vitamin D Metabolism in Patients With Endocrine DisordersCompletedNCT04844164Phase 1
• Postoperative Thrombosis Prevention in Patients With CDActive, not recruitingNCT04486859Not applicable
• Nailfold Capillaroscopy Evaluation in Cushing Syndrome PatientsStatus unknownNCT04433819
• Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s DiseaseWithdrawnNCT04339751Phase 2
• Hair Cortisol and Cushing's DiseaseCompletedNCT04201444Not applicable
• Diagnostic Yield of Deep Learning Based Denoising MRI in Cushing's DiseaseTerminatedNCT04121988
• Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of HypercorticismsActive, not recruitingNCT03974789
• Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseCompletedNCT03774446Phase 2
• Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruitingNCT03604198Phase 2
• Seoul National University Pituitary Disease Cohort StudyStatus unknownNCT03474601
• Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's DiseaseCompletedNCT03346954Not applicable
• The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)Status unknownNCT03343470
• Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015WithdrawnNCT03297892
• Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 InhibitionCompletedNCT03111810Phase 2
• Adipokine Profile in Patients With Cushing's Disease on Pasireotide TreatmentCompletedNCT03080181Phase 4
• Assessment of Persistent Cognitive Impairment After Cure of Cushing's DiseaseCompletedNCT02603653Not applicable
• Cushing's Disease ComplicationsCompletedNCT02568982
• Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's DiseaseStatus unknownNCT02484755Phase 2
• Cushing´s Disease Epidemiology in SwedenCompletedNCT02350153
• The Factors Associated With the Recurrence in Patients With Cushing DiseaseCompletedNCT02233335
• Mifepristone in Children With Refractory Cushing's DiseaseWithdrawnNCT01925092Phase 3
• Effects of Hormone Stimulation on Brain Scans for Cushing s DiseaseCompletedNCT01459237Early Phase 1
• Study of Cabergoline in Treatment of Corticotroph Pituitary TumorCompletedNCT00889525Phase 3
• Long-term Cardiovascular Risk in Cured Cushing's PatientsTerminatedNCT00881283
• Preoperative Bexarotene Treatment for Cushing's DiseaseStatus unknownNCT00845351Phase 1/2
• A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of HypercortisolemiaTerminatedNCT00796783

← Pituitary ACTH Hypersecretion overview